HCC heterogeneity: molecular pathogenesis and clinical implications.

CONCLUSION: New biological therapies targeting components of the tumoral or peritumoral microenvironment are crucial to the fight against HCC. However, biological redundancies and the presence of several growth factors, hormones, cytokines, etc., potentially involved in HCC tumor progression make it difficult to assess the best target. Sorafenib, a multi-tyrosine kinase inhibitor, blocks the functions of different growth factors present in the tissue microenvironment. The use of Sorafenib in patients with HCC offers a new approach to the therapy of this disease, stimulating research focusing on the development of drugs based on new molecular and pathogenic insights. PMID: 19478390 [PubMed - indexed for MEDLINE]
Source: Analytical Cellular Pathology - Category: Cancer & Oncology Tags: Cell Oncol Source Type: research